Stemline Therapeutics Inc

Stemline Therapeutics is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The company's product, ELZONRIS? (tagraxofusp-erzs; SL-401) has been approved by the U.S. Food and Drug Administration for the treatment of blastic plasmacytoid dendritic cell neoplasm in adult and pediatric patients two years and older. The company's pipeline of product candidates includes: SL-801 for patients with solid tumors; SL-701, an immunotherapeutic, which has completed a Phase 2 trial in patients with second-line glioblastoma; and SL-901, an oral, small molecule kinase inhibitor, assessed in Phase 1 trial of patients with solid tumors.
  • TickerSTML
  • ISINUS85858C1071
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

Dropping Coverage Due to Announced Acquisition

Wedbush Research

Wedbush Morning Call - May 05 2020 6:51AM

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

Dropping Coverage Due to Announced Acquisition

Wedbush Research

Wedbush Morning Call - May 05 2020 6:51AM

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

DOWNGRADING to NEUTRAL, Menarini to Acquire STML

Wedbush Research

Wedbush Morning Call - May 04 2020 6:50AM

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ValuEngine Rating and Forecast Report for STML

ResearchPool Subscriptions

Get the most out of your insights

Get in touch